| Primary |
| Product Used For Unknown Indication |
32.3% |
| Diverticulitis |
8.1% |
| Drug Use For Unknown Indication |
5.7% |
| Hypertension |
5.4% |
| Clostridial Infection |
5.3% |
| Infection |
4.5% |
| Diarrhoea |
3.5% |
| Prophylaxis |
3.3% |
| Crohn's Disease |
3.2% |
| Pain |
3.2% |
| Clostridium Difficile Colitis |
3.1% |
| Bacterial Infection |
2.9% |
| Colitis |
2.6% |
| Sepsis |
2.6% |
| Pneumonia |
2.5% |
| Urinary Tract Infection |
2.4% |
| Giardiasis |
2.3% |
| Helicobacter Infection |
2.3% |
| Rheumatoid Arthritis |
2.3% |
| Osteoarthritis |
2.1% |
|
| Drug Hypersensitivity |
31.5% |
| Vomiting |
10.3% |
| Neuropathy Peripheral |
6.6% |
| Rash |
5.0% |
| Pyrexia |
4.7% |
| Urticaria |
4.7% |
| Weight Decreased |
4.0% |
| Paraesthesia |
3.8% |
| Thrombocytopenia |
3.7% |
| Drug Ineffective |
3.5% |
| No Adverse Event |
3.0% |
| Nausea |
2.4% |
| Toxic Skin Eruption |
2.4% |
| Convulsion |
2.3% |
| Neutropenia |
2.3% |
| Renal Failure Acute |
2.3% |
| Dysgeusia |
2.1% |
| Pruritus |
1.9% |
| Vertigo |
1.9% |
| Hypersensitivity |
1.7% |
|
| Secondary |
| Product Used For Unknown Indication |
36.2% |
| Drug Use For Unknown Indication |
15.3% |
| Crohn's Disease |
7.2% |
| Hypertension |
4.4% |
| Diverticulitis |
3.7% |
| Pneumonia |
3.7% |
| Infection |
2.9% |
| Rheumatoid Arthritis |
2.7% |
| Colitis Ulcerative |
2.6% |
| Peptic Ulcer |
2.5% |
| Prophylaxis |
2.2% |
| Pyrexia |
2.2% |
| Sepsis |
2.1% |
| Diarrhoea |
2.0% |
| Lung Disorder |
2.0% |
| Acquired Immunodeficiency Syndrome |
1.8% |
| Pain |
1.7% |
| Acute Myeloid Leukaemia |
1.6% |
| Urinary Tract Infection |
1.6% |
| Clostridial Infection |
1.6% |
|
| Vomiting |
12.4% |
| Thrombocytopenia |
10.2% |
| Drug Hypersensitivity |
8.1% |
| Toxic Epidermal Necrolysis |
7.8% |
| Weight Decreased |
6.2% |
| Pyrexia |
5.9% |
| Organising Pneumonia |
4.6% |
| Toxic Skin Eruption |
4.6% |
| Cholestasis |
4.3% |
| Colitis |
4.3% |
| Neuropathy Peripheral |
3.8% |
| Urticaria |
3.8% |
| Dermatitis Exfoliative |
3.5% |
| Peripheral Sensory Neuropathy |
3.5% |
| Acute Generalised Exanthematous Pustulosis |
3.0% |
| Hepatocellular Injury |
3.0% |
| Renal Failure Acute |
3.0% |
| Cytolytic Hepatitis |
2.7% |
| Neutropenia |
2.7% |
| Paraesthesia |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
28.9% |
| Drug Use For Unknown Indication |
21.3% |
| Crohn's Disease |
17.3% |
| Pain |
4.9% |
| Prophylaxis |
3.7% |
| Multiple Myeloma |
2.8% |
| Hypertension |
2.3% |
| Nausea |
2.3% |
| Colitis Ulcerative |
2.0% |
| Contraception |
1.7% |
| Depression |
1.7% |
| Diarrhoea |
1.4% |
| Anxiety |
1.4% |
| Gastrooesophageal Reflux Disease |
1.2% |
| Osteoporosis |
1.2% |
| Breast Cancer Metastatic |
1.2% |
| Infection |
1.2% |
| Breast Cancer |
1.1% |
| Sepsis |
1.1% |
| Constipation |
1.1% |
|
| Vomiting |
17.2% |
| Weight Decreased |
13.0% |
| Pulmonary Embolism |
6.1% |
| Crohn's Disease |
6.0% |
| Pyrexia |
5.8% |
| Thrombocytopenia |
5.8% |
| Sepsis |
5.1% |
| Pain |
4.2% |
| Urinary Tract Infection |
3.7% |
| White Blood Cell Count Increased |
3.4% |
| Diarrhoea |
3.2% |
| Renal Failure |
3.2% |
| Tachycardia |
3.2% |
| Weight Increased |
3.1% |
| Viral Infection |
3.1% |
| Nausea |
3.0% |
| Rash |
2.8% |
| Renal Failure Acute |
2.8% |
| Death |
2.6% |
| Respiratory Failure |
2.6% |
|
| Interacting |
| Product Used For Unknown Indication |
26.0% |
| Drug Use For Unknown Indication |
8.7% |
| Abdominal Pain Upper |
5.8% |
| Diverticular Perforation |
5.8% |
| Gastroenteritis Viral |
5.8% |
| Pelvic Inflammatory Disease |
5.8% |
| Pyrexia |
5.8% |
| Abdominal Pain |
3.8% |
| Atrial Fibrillation |
3.8% |
| Brain Neoplasm Malignant |
3.8% |
| Diverticulitis |
3.8% |
| Infection |
3.8% |
| Glioblastoma Multiforme |
2.9% |
| Urinary Tract Infection |
2.9% |
| Bacterial Infection |
1.9% |
| Epilepsy |
1.9% |
| Escherichia Sepsis |
1.9% |
| Gastric Ulcer |
1.9% |
| Metastatic Malignant Melanoma |
1.9% |
| Pulmonary Embolism |
1.9% |
|
| International Normalised Ratio Increased |
13.8% |
| Muscle Spasms |
10.3% |
| Drug Interaction |
6.9% |
| Oesophagitis Ulcerative |
6.9% |
| Status Epilepticus |
6.9% |
| White Blood Cell Count Decreased |
6.9% |
| Blood Potassium Increased |
3.4% |
| Cholestasis |
3.4% |
| Dry Mouth |
3.4% |
| Epistaxis |
3.4% |
| Helicobacter Infection |
3.4% |
| Overdose |
3.4% |
| Pelvic Inflammatory Disease |
3.4% |
| Pyrexia |
3.4% |
| Renal Failure |
3.4% |
| Rhabdomyolysis |
3.4% |
| Skin Reaction |
3.4% |
| Unevaluable Event |
3.4% |
| Vaginal Infection |
3.4% |
| Weight Decreased |
3.4% |
|
